The Most Effective, Versatile, and Efficient Devices for Pain Relief, Accelerated Healing, and More

Save Time & Physical Exertion

Non-invasive 10 – 30 minute treatments that are easy to set up and administer.

Expand Treatment Range

Pre / Rehabilitation, acute and chronic conditions, pain-sensitive cases, and more.

Get The Best Results

Relieve pain, accelerate healing, reduce inflammation, improve mobility, and more.

Erchonia’s non-thermal lasers are the only Low-Level Laser Therapy (LLLT) devices to be FDA Market Cleared for pain relief – FDA Level One (510k) clearance is the ‘gold standard’, requiring placebo controlled, double blind, randomised, and multi-centre studies. The treatments are short, effective, and easy to administer, saving time and minimising physical exertion. There is no associated pain or reported side effects, and the technology is very safe with no health risks. Used on their own or as an adjunct, Erchonia® lasers can be easily integrated into your current skill set, and the devices are effective on a wide variety of conditions, allowing you to expand your treatment range and grow your clinic. We provide the training, ongoing support, and marketing, so you can focus on what matters most – your patients.

An XLR8 pain relief laser

XLR8®

Details …
About XLR8® Laser for Pain Relief
About XLR8® Laser for Pain Relief

The XLR8® Laser is a cordless handheld device with a simple graphic interface and preset / customisable protocols. It is the only LLLT device to be FDA Market Cleared for treating back, shoulder, and heel pain, and provides fantastic results in convenient pain-free sessions.

How Erchonia® Lasers Work
How Erchonia® Lasers Work

XLR8® delivers parcels of light energy into the cell which the cell can use, and the parcels are delivered in the most effective and efficient way. This added energy fuels key processes, stimulating healing, relieving pain, reducing inflammation, and restoring function. For a more detailed explanation, please see the ‘What is the Technical Explanation for How Erchonia® Lasers Work?’ FAQ below.

> Download Data Sheet

An EVRL handheld pain relief laser therapy device

EVRL®

Details …
About EVRL® Laser for Pain Relief
About EVRL® Laser for Pain Relief

New in series: The EVRL® Laser is a cordless handheld device with a simple graphic interface and preset / customisable protocols.

EVRL® has the same properties and mechanisms of action as its predecessor, XLR8®, but the addition of a violet wavelength allows the device to treat a larger variety of conditions (e.g. bacterial, fungal, or viral infections).

> Download Data Sheet

Base Station – three handheld pain relief laser instruments from Erchonia

Base Station

Details …

With the Base Station, you can choose three lasers from XLR8® and EVRL® (e.g. two XLR8® and one EVRL® – the best of both worlds).

This combination allows you to treat multiple patients simultaneously, and / or to carry out advanced protocols on patients by using multiple lasers on several different points of the body at the same time.

> Download Data Sheet

FX635 pain relief cold laser therapy device

FX 635®

Details …
About FX635® Laser for Pain Relief
About FX635® Laser for Pain Relief

The FX 635® Laser is Erchonia’s flagship device for pain management:

• The quickest and most efficacious results as per clinical studies.

• Completely hands free so you can save on staff costs and increase profits.

• The best marketability of any pain relief laser in the world due to its US FDA-clearances.

> Download Data Sheet

Case Studies

Physicians, surgeons, chiropractors, physiotherapists, and osteopaths report that Erchonia® lasers can be used to effectively treat osteopenia, advanced arthritis, chronic inflammation, adhesive capsulitis, plantar fasciitis, post-concussion syndrome, whiplash, muscle / tendon / ligament / joint damage or tension, contusions, wound management, infection, skin lesions, acne, and much more.

Henry Cejudo & Dr. Burdorf Interview | Erchonia® Lasers
Henry Cejudo & Dr. Burdorf Interview | Erchonia® Lasers

Mixed Martial Arts Star Henry Cejudo and Erchonia®

“I have treated Henry Cejudo with Erchonia lasers for concussions, cervical whiplash, post left shoulder surgery, rib contusions, and sprains in every region for the past 12 years. I now have a reputation for treating numerous combat athletes in the UFC and Bellator MMA with similar complaints.”

EVRL® Testimonial by Martin Anderson (DC) | Erchonia® Lasers
EVRL® Testimonial by Martin Anderson (DC) | Erchonia® Lasers

EVRL® Testimonial by Martin Andersen (DC CCEP MCC)

“As a busy practitioner, I need tools that are time efficient, effective, and easy to use between different practitioners. I came across Erchonia and was impressed by the amount of research behind Cold Laser Therapy. EVRL is quick, efficient, and very versatile. It broadened my treatment protocol options.”

How to Choose the Right Device for Your Clinic

All lasers in the Erchonia® portfolio would be a valuable addition

XLR8
Red 635nm
2 Diodes
EVRL
Red 635nm
Violet 405nm
2 Diodes

Base Station
3x
Handheld
Lasers of
Choice From EVRL & XLR8
FX635
Red 635nm
3 Rotating Diodes
Unmanned
Collimated, monochromatic, coherent true laser
Easy to set up and administer
Lightweight and portable
Ideal for offices with limited space
No pain or discomfort felt by client
Safe and effective
Clinically proven with placebo controlled, double blind, randomised, and multi-centre studies
US FDA-approved & CE marked
All pain management
Accelerated healing
Best for para-sympathetic nervous system
Can be used for sympathetic AND para-sympathetic nervous system
Musculoskeletal management
Functional neurology
Gut to brain axis
Fungal and bacterial management
Best for acne and skin conditions
Sports rejuvenation
Health / wellbeing
Pre / Rehabilitation
Ideal for high volume clinics
Plug, play, and walk away

Recent Testimonials

From chiropractors and physiotherapists, to physicians and surgeons, to professional sports clubs and sports medicine practises, here’s what our clients have to say about our FDA Market Cleared non-thermal Low-Level Lasers.

“I am thrilled to have bought the EVRL, now I have it I don’t know how I did without it. I was very sceptical when I went to the Erchonia seminar but became increasingly amazed by its potential and effectiveness. It has increased the scope of my practice, as well as giving me confidence to treat people with challenging conditions such as osteopenia, advanced arthritis, chronic inflammation, and those with low pain thresholds.”

Nell Chandler, DC

Chiropractor

“What we love about the Erchonia non-thermal lasers is that they utilise electromagnetic energy transfer. This enables healing at a cellular level. Their lasers have enabled us to treat tissue injury and reduce pain in the most efficacious manner vs other modalities available. The addition of the Erchonia laser system has revolutionised our practises and allowed us to attain never seen before patient outcomes.”

Dr. Rob Silverman, DC

Chiropractor

“As a diplomate of the American Chiropractic Neurology Board, I have an interest in functional neurology and was intrigued by the EVRL’s apparent effectiveness on neurological disorders such as senile dementia, as well as musculoskeletal problems. The pain relief laser has become an indispensable addition to my practice, helping to reduce the physical load on my body, speed up recovery, and increase mobility in patients.”

Julia Waring, DC

Chiropractor

FAQs

What is the Technical Explanation for How Erchonia® Lasers Work?

Erchonia® lasers utilise true laser technology, optimising photonic energy delivery through the use of monochromatic, collimated, and coherent beams of light. That is, the light emitted by a true laser is composed from photons that have the same wavelength (monochromatic), travel in the same direction / do not disperse (collimated), and are in phase in space and time (coherent). These three properties of true lasers make them the most effective and efficient devices within the Laser Therapy sector.

Erchonia® lasers generate therapeutic effects through stimulating and enhancing specific biochemical processes within cells. More specifically, utilising the first law in photochemistry (Grotthuss-Draper law), laser energy is transferred to cytochrome c oxidase (CcO) – a respiratory energy-transducing enzyme which is involved in the electron transport chain in mitochondria. This energy transfer causes photodissociation of inhibitory nitric oxide from CcO, leading to an enhancement of enzyme activity, electron transport, mitochondrial respiration, and adenosine triphosphate (ATP) production. Consequently, by altering the cellular redox state, Erchonia® lasers induce the activation of numerous intracellular signalling pathways, and alter the affinity of transcription factors concerned with cell proliferation, survival, repair, and regeneration.

Erchonia® lasers were specifically designed to deliver the optimal amount of energy required to stimulate and enhance cell function while not damaging cells or producing painful heat sensations – all of our non-thermal Low-Level Laser Therapy (LLLT) devices are classified as ‘Class II Lasers’ by the FDA in virtue of their low output and very low risk of hazard.

What is the Scientific Evidence Behind Erchonia® Lasers?

All studies carried out to obtain FDA-approvals are Level One (510k), so are placebo controlled, double blind, randomised, and multi-centre – the most credible certifications of all pain management devices on the market today.

The following list shows the clinical trials and an outline of their progress. As a company, to protect our intellectual assets, not all clinical trials we are involved with are made public so as to maintain our competitive advantage. As such, not all clinical trials are listed below.

Please note: There are hundreds of double blind medical studies confirming the effectiveness of Low-Level Laser Therapy (LLLT), and every year there are more than 250 new publications. Below is a list of Erchonia-specific studies for FDA-clearance.

1) Market Clearance for Relief of Chronic Musculoskeletal Pain (FX 635) — 2019 — A collection of placebo-controlled, randomized, double-blind, parallel-group, multi-center clinical studies.
FDA-clearance – K190572

2) Market Clearance to Treat Chronic Low Back Pain (FX 635) — 2018 — Placebo-controlled, randomized, double-blind, parallel-group, multi-center clinical study.
FDA-clearance – K180197
To view NIH clinical trial records, click here.

3) Erchonia EVRL (EVRL) – 2016
a. while using the red diode, for adjunctive use in providing temporary relief of minor chronic neck and shoulder pain of musculoskeletal origin.
b. and while using the violet diode, to treat dermatological conditions, and specifically indicated to treat moderate inflammatory Acne Vulgaris.
FDA-clearance – K152196

4) Adjunct to Chronic Heel Pain Arising from Plantar Fasciitis Using the Erchonia FX635 Laser — 2012 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
FDA-clearance – K132940
Study results published in the American Orthopaedic Foot & Ankle Society April 2014
To view NIH clinical trial records, click here.

5) Equine Wound Healing – 2011 — Sponsor, placebo controlled, clinical study.
Study completed from Feb. 2011-April 2011.
Monitored by Hank Jann, DVM, MS, DAVCS from Oklahoma State University.

6) Equine Wound Healing – 2011 — Sponsor, Case Study.
Study completed from Nov. 2010-March 2011.
Monitored by Hank Jann, DVM, MS, DACVS from Oklahoma State University.

7) Pain Associated With Breast Augmentation Surgery / Low-Level Laser — 2007 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
Results used to obtain FDA-clearance – K072206
To view NIH clinical trial records, click here.

8) Acne Vulgaris — Dermatological Conditions / Low-Level Laser — 2005 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
FDA-clearance – K050672

9) Low-Level Laser Light Therapy as an Aid to Liposuction and Reduction of Pain Associated With Surgery — 2004 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
Study results used to obtain FDA-clearance – K041139
To view NIH clinical trial records, click here.

10) Chronic Neck and Shoulder Pain / Low-Level Laser — 2001 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
Study results used to obtain FDA-clearance – K012580
To view NIH clinical trial records, click here.

11) Chronic Neck and Shoulder Pain / Low-Level Laser — 2000 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
First study done in support of 510(k) submission, second study requested by FDA.

What Conditions Can Erchonia® Pain Relief Lasers Treat?

Physicians, surgeons, chiropractors, physiotherapists, and osteopaths report that Erchonia® lasers can be used to effectively treat osteopenia, advanced arthritis, chronic inflammation, adhesive capsulitis, plantar fasciitis, nerve function and health (including vagus nerve), brain function, post-concussion syndrome, whiplash, muscle / tendon / ligament / joint damage or tension, contusions, bacterial / fungal / viral infection, wound management, skin lesions, acne, and much more.

What is the Technical Difference Between Erchonia® and Other Technologies in This Market?

To understand the difference between Erchonia® and other technologies in this market, it is first important to distinguish between High-Level Laser Therapy (HLLT) and Low-Level Laser Therapy (LLLT):

  • HLLT devices are classified as ‘Class IV Lasers’ by the FDA in virtue of having a power output that’s greater than 500mW (i.e. high risk of hazard).
  • LLLT devices are classified as either ‘Class IIIB Lasers’, ‘Class IIIR Lasers’, or ‘Class II Lasers’ in virtue of having a power output of 5-500mW, 1-5mW, or <1mW respectively (i.e. lower risk of hazard).

The vast majority of HLLT devices have longer near-infrared (NIR) wavelengths – there is a common misconception, often propagated by the manufacturers of such devices, that high power with longer wavelengths results in:

  1. Deeper penetration, allowing for the treatment of a wider range of conditions.
  2. More efficacious results (due to the delivery of more energy into the cells).

This however, is not correct for the following well-documented reasons:

  1. Due to the high absorption rate of laser light by water at wavelengths greater than 950nm, most of the energy produced at this wavelength (or above) is absorbed before penetrating the dermis.
  2. The key principle behind Laser Therapy is to generate therapeutic effects by stimulating and enhancing specific biochemical processes within cells (c.f. ‘What is the Technical Explanation for How Erchonia® Lasers Work?’ FAQ). However, there is an optimal ‘dose’ of laser energy (typically 2-4 joules / cm²) required for stimulating and enhancing the desired biochemical processes – HLLT devices exceed this optimal level.

Put simply, HLLT devices deliver too much energy at inefficient wavelengths, resulting in a lack of efficacy and increased costs.

To add to this, the high outputs used by such devices produce painful heat sensations, further limiting their scope of treatment.

In essence, HLLT devices should only be used for laser surgery and tissue ablation – the high outputs are effective for cell destruction, but are not suited for therapeutic purposes, contrary to the claims of Class IV manufacturers.

LLLT devices, on the other hand, aim to deliver energy via low output, short wavelength beams of light. The general theory is that this approach transfers the optimal amount of energy for stimulating and enhancing cell function, while not damaging cells or producing painful heat sensations.

Within the LLLT sector however, some of the higher output devices still generate heat / pain. Furthermore, many devices are advertised as ‘lasers’, when in fact they are Light Emitting Diodes (LEDs) or Superluminescent Diodes (SLDs). In contrast to LEDs or SLDs, ‘true’ lasers generate monochromatic, collimated, and coherent beams of light. These three properties of true lasers make them the most effective and efficient LLLT devices (c.f. ‘What is the Technical Explanation for How Erchonia® Lasers Work?’ FAQ).

To separate Erchonia® from such technologies, and from HLLT more generally, we say that Erchonia® lasers are ‘non-thermal, true lasers’. That is, our lasers do not produce any heat or painful sensations, and are monochromatic, collimated, and coherent.

Are There Other ‘Clinically Proven’ or ‘FDA-Cleared’ Technologies in this Sector?

The efficacy of Erchonia® lasers has been scientifically proven with placebo controlled, double blind, randomised, and multi-centre studies – Level One (510k) FDA-clearance is the gold standard, and is one of the hardest certificates to obtain. Many competing companies advertise their products as ‘clinically proven’, guaranteeing ‘instant results’. However, these claims are often not backed by comprehensive clinical evidence (c.f. ‘Are Class IV Lasers Backed by Scientific Evidence’ FAQ).

It is also sometimes the case that competing technologies are marketed as ‘FDA-cleared’, but this clearance is quite weak or not related to pain management. For example, perhaps the clearance is for wrinkles and rhytids. We always recommend that you ask for details of the FDA-clearances and make an informed decision – pay particular attention to the scope of the clearance, how many patients participated, whether it was placebo controlled, double blind, and randomised, how many peer reviewed published articles they have, and what the adverse reactions / side effects were (we would be happy to provide this information for you).

Are Class IV Lasers Backed by Scientific Evidence?

There has never been a Class IV laser that has proved its efficacy through clinical research – all Class IV lasers failed to conduct the necessary scientific studies. Instead, the companies took the path of least resistance and filed what is called a ‘Substantial Equivalent’. To get market clearance this way, all one has to do is to say that the product shares the same characteristics and is intended for the same use as the predicate device – no research is required.

Below is the actual intended use from the FDA and the predicate devices the companies used to garner clearance to market their Class IV lasers.

FDA Comments Regarding Class IV Lasers

K-Laser

The intended use / indications for use:

– Infrared therapy to provide topical heating for:

  • Temporary increase in local blood circulation.
  • Temporary relief of minor muscles and joint aches, pains, and stiffness.
  • Relaxation of muscles.
  • Muscles spasms.
  • Minor pain and stiffness associated with arthritis.

Substantial Equivalence Rationale: K-Laser generates infrared therapy for treatment of selected medical conditions and shares the same or similar basic characteristics and the same intended use as the predicate device.

Predicate Devises:

  • ALT Laser, Model VTR 75 – Cleared under K031613.
  • Vectra Genisys Laser System – Cleared under K040662.
  • Solaris D890 – Cleared under K040729.

Lite Cure / Companion

The intended use / indications for use:

– Infrared therapy to provide topical heating for:

  • Temporary increase in local blood circulation.
  • Temporary relief of minor muscles and joint aches, pains, and stiffness.
  • Relaxation of muscles.
  • Muscles spasms.
  • Minor pain and stiffness associated with arthritis.

Predicate Devices Used to Gain FDA Market Clearance:

  • K-Laser Therapy Probe – Cleared 1mder K050070 market clearance.
  • ALT Laser, Model VTR 75 – Cleared under K03162 market clearance.

Class IV laser companies claim to the governing bodies that they are the same as Class III devices proven by the predicate devices they filed off of. However, they often market as being superior, even though the indications for use are the same.

What Are the Biological Effects of Low-Level Laser Therapy (LLLT)?

Clinical studies and trials of Laser Therapy technologies indicate the following beneficial effects of Low-Level Laser Therapy (LLLT).

  1. Anti-Inflammation. LLLT creates an anti-edema effect by dilating blood vessels and activating the lymphatic drainage system (which drains swollen areas). This reduces swelling caused by trauma or inflammation.
  2. Anti-Pain (Analgesic). LLLT exerts a very beneficial effect on pain in multiple ways: It partially blocks neural transmission of pain signals to the brain; It decreases nerve sensitivity; It lessens pain by reducing edema; It helps to increase the production of high levels of painkilling chemicals such as endorphins, enkephalins, and opioids from the brain and adrenal gland.
  3. Accelerated Tissue Repair and Cell Growth. Photons of light from lasers penetrate deeply into tissues and accelerate cellular reproduction and growth. The laser light also increases the energy available to the cell by increasing ATP production so that the cell can take on nutrients faster and get rid of waste products. As a result of exposure to laser light, all cells, including the cells of tendons, ligaments, and muscles, are repaired faster.
  4. Improved Vascular Activity. LLLT significantly increases the formation of new capillaries in damaged tissue, which speeds up the healing process, closes wounds more quickly, and reduces scarring. LLLT also causes vasodilation – an increase in the diameter of blood vessels – which improves the delivery of blood and healing elements to damaged tissues.
  5. Increased Metabolic Activity. LLLT stimulates higher outputs of specific pro-healing enzymes in blood cells, along with improved oxygen and nutrient delivery.
  6. Trigger Points and Acupuncture Points. LLLT stimulates muscle trigger points and acupuncture points on a non-invasive basis, providing musculoskeletal pain relief.
  7. Reduced Fibrous Tissue Formation. LLLT reduces the formation of scar tissue following damage from cuts, scratches, burns, or surgery.
  8. Improved Nerve Function. Slow recovery of nerves in damaged tissue results in impaired sensory and motor function. LLLT speeds up the process of axonal regeneration and nerve cell reconnection, and increases the amplitude of action potentials to optimize muscle action.
  9. Immunoregulation. LLLT directly affects immunity status by stimulating the production of immunoglobulins and lymphocytes, and by improving the ease of penetration of white blood cells into damaged tissue.
  10. Faster Wound Healing. LLLT stimulates fibroblast development in damaged tissue. Fibroblasts are the building blocks of collagen, which is the essential protein required to replace old tissue or repair tissue injuries. As a result, LLLT is effective on open wounds and burns.
Are There Any Conditions Which Would Prevent Patients From Receiving the Treatments?

There are no code regulated contraindications, however, since there are no long-term evaluations on certain conditions, we do not recommend using Erchonia® non-thermal lasers on pregnant women, clients with a pacemaker, or clients with photosensitive epilepsy. We also do no recommend using our devices over an area of known cancer.

Will Erchonia® Lasers Cause Pain or Burning?

Erchonia® are true Non-Thermal Low-Level Lasers and cause no pain or health risks.

How Long is a Treatment?

Erchonia® treatments are just 10-30 minutes long and are relaxing to administer, allowing you to take the pressure off your hands and body.

What do Erchonia® Lasers Treat and How Are They Used?

Erchonia® lasers are used in many areas, such as 360-degree fat loss, body sculpting, cellulite reduction, pain management, pre / postsurgical healing, pre / rehabilitation, and nail and skin pathologies (e.g. onychomycosis (nail fungus), acne, and more).

Not only do our lasers treat specifics, but they also empower the body to function efficiently due to the beneficial effects they have on our cells.

Why Choose Erchonia®?

World Leaders in Laser Therapy Technology

With over 25 years of experience, 16,000+ devices in the market, and 18 FDA-clearances, Erchonia® Corporation are world leaders in Laser Therapy technology. Our range of non-thermal Low-Level Laser Therapy (LLLT) devices are used in many areas, including pain relief, fat removal, cellulite reduction, fungal nail treatment, and more. Based in the UK, Erchonia Lasers Ltd are a subsidiary organisation. We provide personal support to companies in Europe, Middle East, and Africa… Read More

About Erchonia® Corporation
About Erchonia® Corporation

91% Customer Satisfaction Rating

Our clients say it all: best products, service, training, and support.

Over 25 Years of Experience

Founded in 1996 – first Low-Level Laser in the world to gain FDA market clearance.

18 FDA (Level One 510k) Clearances

Proven by placebo controlled, double blind, randomised, and multi-centre studies.

16,000+ Devices in the Market

Leaders in the field with over $5 million invested in R&D at any one time.